Ardana: A Global Company Based in Edinburgh
Astonishing advances in life sciences and biotechnology have created a whole new industry with tremendous growth potential and far reaching consequences for the way we live. A particularly exciting area where innovative research is contributing to new knowledge is reproductive health. Advances in this area will bring improvements in fertility treatments, more convenient contraceptives, novel treatments for gynecological disorders, and innovative obstetric products. Ardana was created in 2000 to meet the needs of this reproductive health market estimated to be worth £10.2 billion per year.
Astonishing advances in life sciences and biotechnology have created a whole new industry with tremendous growth potential and far reaching consequences for the way we live. A particularly exciting area where innovative research is contributing to new knowledge is reproductive health. Advances in this area will bring improvements in fertility treatments, more convenient contraceptives, novel treatments for gynecological disorders, and innovative obstetric products. Ardana was created in 2000 to meet the needs of this reproductive health market estimated to be worth £10.2 billion per year.
Ardana was established to commercialize research undertaken at the Medical Research Council's Human Reproductive Sciences Unit (HRSU). The HRSU has been at the forefront of research in the human reproductive system for the last 30 years, and the unit is one of only four academic centers of excellence in human reproductive biology in the world.
Since its inception, Ardana has raised £34.6 million in three funding rounds. Ardana investors include Techno Venture Management, Merlin Biosciences, MVM, ABN-AMRO Capital, 3i, ISIS Equity Partners, Scottish Widows Investment Partnership, Mitsubishi, and Green Highlander.
Ardana is a global company in the truest sense of the word. The company, which is based in the center of Edinburgh's stunning new town, collaborates with companies across the globe. The excellence of the science undertaken at the HRSU and Ardana's close links with other local centers of excellence, such as the University of Edinburgh Department of Obstetrics and Gynecology, make Edinburgh a strong location for the company.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
AES Clean Technology Launches Next-Generation OSM Utility Solution for Cleanrooms at INTERPHEX 2025
April 2nd 2025Officially launched at INTERPHEX 2025, the Omni ASCENT is a next-generation off-site manufactured vertical utility solution that offers optimized cleanroom flexibility and efficiency.
